Table 2. Treatment characteristics for entire group and ReCH and ReIn group.
| Characteristics | % (N) | ReCH % (n) |
ReIn % (n) |
|---|---|---|---|
| Anti-EGFR—1st exposure | |||
| Cetuximab | 94.1 (64) | 100 (17) | 92.2 (47) |
| Panitumumab | 5.9 (4) | 0 (0) | 7.8 (4) |
| Best response—1st exposure | |||
| SD | 28.1(18) | 62.5 (10) | 16.7 (8) |
| PR | 57.8 (37) | 31.3 (5) | 66.6 (32) |
| CR | 12.5 (8) | 0 (0) | 16.7 (8) |
| PD | 1.6 (1) | 6.2 (1) | 0 (0) |
| Reason for 1st discontinuation | |||
| PD | 25 (17) | 100 (17) | 11.8 (6) |
| Toxicity | 8.8 (6) | 0 | 1.0 (2) |
| Patient decision | 1.5(1) | 0 | 45.1(23) |
| Drug Holiday | 33.8 (23) | 0 | 23.5 (12) |
| Surgery | 17.6 (12) | 0 | 7.8 (4) |
| Maintenance | 5.9 (4) | 0 | 9.8 (5) |
| Others | 7.4 (5) | 0 | 11.8 (6) |
| Line of re-exposure | |||
| 2nd | 22.1 (15) | 0 (0) | 29.4 (15) |
| 3rd | 39.7 (27) | 29.4 (5) | 43.2 (22) |
| ≥4th | 38.2 (26) | 70.6 (12) | 27.4 (14) |